Save the Children, drug co. GSK in new partnership
GlaxoSmithKline is giving Save the Children $23 million and entering into a five-year partnership with the charity to try to save the lives of 1 million children. Full story
GlaxoSmithKline is giving Save the Children $23 million and entering into a five-year partnership with the charity to try to save the lives of 1 million children. Full story
(Reuters) - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug. Full story
Pharmaceutical company GlaxoSmithKline has reported a 26 percent drop in profits in the first quarter compared to a year ago, as it restructures its manufacturing and research and development divisions. Full story
(Reuters) - GlaxoSmithKline said on Monday it will partner with venture capitalists Avalon Ventures in a deal worth up to $495 million to fund as many as 10 drug-discovery startup companies over the next three years. Full story
LONDON (Reuters) - GlaxoSmithKline, Britain's biggest drugmaker, is placing a small but important bet on a new way of treating diseases by targeting electrical signals in the body. Full story
LONDON (Reuters) - Regulators have delayed approval of an H5N1 bird flu vaccine from GlaxoSmithKline, designed to be used in a pandemic. Full story
Andrew Witty, CEO of GlaxoSmithKline, discusses his company's 2012 earnings and explains why he is optimistic about the company's restructuring plans in Europe.
CNBC's David Faber reports the latest details on GlaxoSmithKline's takeover bid for Human Genome Science.
Triple digit heat follows power outages; Where homes become ovens; Inside Colorado’s burn zone; GlaxoSmithKline pays $3 billion to settle fraud case; Dual-engine failure caused jet crash; Pena Nieto promises to jumpstart Mexico’s economy; Improving firefighter safety; Statue of Liberty replica moves
A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville
GlaxoSmithKline Chief Executive Andrew Witty speaks at the Global Investment Conference in London July 26, 2012. REUTERS/Neil Hall
Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. REUTERS/Toby Melville